🇺🇸 FDA
Patent

US 8268618

Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins

granted A61KA61K48/00A61K48/005

Quick answer

US patent 8268618 (Repressing endogenous CCR5 gene expression in cells using engineered zinc finger proteins) held by Sangamo Biosciences, Inc. expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Biosciences, Inc.
Grant date
Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K48/00, A61K48/005, A61P, A61P11/00